© 2004 BMJ Publishing Group Ltd & Association of Clinical Pathologists
SHORT REPORT
Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
1 Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria
2 Department of Surgery, Division of Biomedical Engineering and Computing, Medical University of Graz
3 Department of Urology, Medical University of Graz
Correspondence to:
Correspondence to:
Dr C Langner
Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; cord.langner{at}meduni-graz.at
Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation.
Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique.
Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not.
Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.
Abbreviations: EGFR, epidermal growth factor receptor; RCC, renal cell carcinoma
Keywords: renal cell carcinoma; epidermal growth factor receptor; immunohistochemical evaluation; prognosis; treatment
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Martin, V, Mazzucchelli, L, Frattini, M
(2009). An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology. J. Clin. Pathol.
62: 314-324
[Abstract] [Full Text] -
Hoffmann, S., Wunderlich, A., Lingelbach, S., Musholt, P. B., Musholt, T. J., von Wasielewski, R., Zielke, A.
(2008). Expression and Secretion of Endostatin in Thyroid Cancer. Ann. Surg. Oncol.
15: 3601-3608
[Abstract] [Full Text] -
Schoffski, P., Dumez, H., Clement, P., Hoeben, A., Prenen, H., Wolter, P., Joniau, S., Roskams, T., Van Poppel, H.
(2006). Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol
17: 1185-1196
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
